|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
18,220,000 |
Market
Cap: |
61.77(M) |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0.9225 - $3.4 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Miromatrix Medical is a life sciences company focused on a technology for bioengineering transplantable organs to help save and improve patients' lives. Co.'s Bioengineered Organ Pipeline includes: MiroliverELAP, which is Co.'s External Liver Assist Product and is designed to provide liver dialysis for acute liver failure patients; Miroliver, which is Co.'s implantable bioengineered liver that intended to treat patients with acute and chronic liver failure in collaboration with the Mayo Clinic; and Mirokidney, which is Co.'s implantable bioengineered kidney that intended to treat patients with end-stage renal disease.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
225,000 |
Total Buy Value |
$0 |
$0 |
$0 |
$360,000 |
Total People Bought |
0 |
0 |
0 |
8 |
Total Buy Transactions |
0 |
0 |
0 |
8 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Burke Willaim P |
|
|
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
80,155 |
0.01 |
25% |
|
Erb John L |
|
|
2023-03-10 |
4 |
B |
$1.60 |
$50,000 |
D/D |
31,250 |
56,260 |
0.01 |
25% |
|
Barry John Joseph |
VICE PRESIDENT OF R&D |
|
2023-03-10 |
4 |
B |
$1.60 |
$10,000 |
D/D |
6,250 |
35,485 |
0.01 |
25% |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2023-01-13 |
4 |
D |
$3.26 |
$14,628 |
D/D |
(4,487) |
365,026 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2023-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
369,513 |
|
- |
|
Douglas James Michael |
CHIEF FINANCIAL OFFICER |
|
2023-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
20,000 |
20,000 |
|
- |
|
Barry John Joseph |
VICE PRESIDENT OF R&D |
|
2023-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
29,235 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2022-12-06 |
4 |
D |
$4.05 |
$46,879 |
D/D |
(11,575) |
319,513 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2022-12-06 |
4 |
OE |
$1.25 |
$46,875 |
D/D |
37,500 |
331,088 |
|
- |
|
Barry John Joseph |
VICE PRESIDENT OF R&D |
|
2022-10-01 |
4 |
D |
$4.38 |
$3,351 |
D/D |
(765) |
19,235 |
|
- |
|
Burke Willaim P |
|
|
2022-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,788 |
48,905 |
|
- |
|
Maag Peter |
|
|
2022-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,788 |
35,009 |
|
- |
|
Buckman Paul |
|
|
2022-08-10 |
4 |
A |
$0.00 |
$0 |
I/I |
12,788 |
21,343 |
|
- |
|
Heine Lisa Wipperman |
|
|
2022-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,788 |
48,905 |
|
- |
|
Erb John L |
|
|
2022-08-10 |
4 |
A |
$0.00 |
$0 |
D/D |
12,788 |
25,010 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2022-03-15 |
4 |
OE |
$1.25 |
$44,298 |
D/D |
35,438 |
293,588 |
|
- |
|
Kattungal Laji |
VICE PRESIDENT OF QUALITY |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
Barry John Joseph |
VICE PRESIDENT OF R&D |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
Niebur Brian |
CHIEF FINANCIAL OFFICER |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
24,668 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2022-01-13 |
4 |
A |
$0.00 |
$0 |
D/D |
50,000 |
258,150 |
|
- |
|
Burke Willaim P |
Director |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
36,117 |
36,117 |
|
- |
|
Heine Lisa Wipperman |
Director |
|
2022-01-03 |
4 |
A |
$0.00 |
$0 |
D/D |
36,117 |
36,117 |
|
- |
|
Barry John Joseph |
Vice President of R&D |
|
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
10,000 |
|
- |
|
Niebur Brian |
Chief Financial Officer |
|
2021-10-01 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
14,668 |
|
- |
|
Ross Jeffrey James |
CHIEF EXECUTIVE OFFICER |
|
2021-06-28 |
4/A |
A |
$0.00 |
$0 |
D/D |
4,400 |
208,150 |
|
- |
|
62 Records found
|
|
Page 2 of 3 |
|
|